ASX Health Stocks: Race Oncology blows past dosing stage of Phase 1, targets Phase 2 - Stockhead

Retrieved on: 2022-05-27 08:41:56

Tags for this article:

Click the tags to see associated articles and topics

ASX Health Stocks: Race Oncology blows past dosing stage of Phase 1, targets Phase 2 - Stockhead. View article details on hiswai:

Excerpt

ASX health stock Race Oncology has completed the dose escalation stage of its Phase 1b/2 Zantrene study into ALM ( (acute myeloid leukemia).

Article found on: stockhead.com.au